NIFTYPHARMA · NSE
Nifty Pharma
Index · View only — not on the trading terminal
₹28,386.9
+0.05% (+₹15.1)
Prev. close
₹28,371.8
Volume
1,66,12,248
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
5 analyst stances · last 90 days · one per analyst
Trackable
none in range
Long-Horizon
none in range
Commentary
5 · 5 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bearish on the Nifty Pharma Index, maintaining a negative outlook as long as it fails to sustain above 22,380. While a p…” | Kunal KambleIndependent | Nifty Pharma | NOT GRADED |
Market commentary · 99 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on the Indian pharma sector, especially large complex generic makers such as Sun Pharma, Cipla and Dr Reddy's. H…” | Deven ChokseyDRChoksey FinServ Pvt. Ltd | Nifty Pharma Index | — | |
| “FIIs have been systematically accumulating stocks in pharmaceuticals and healthcare, along with select digital platform …” | VK VijayakumarGeojit Financial Services | Nifty Pharma | — | |
| “Bullish on the healthcare and lifesciences sectors, noting they are highly active. He also expects the pharma sector to …” | Rahul SarafCiti | Nifty Pharma | — | |
| “Bullish on Nifty Pharma, which has witnessed a retracement but is seeing support emerge around 26,400, aligned with its …” | Hitesh TailorChoice Equity Broking | Nifty Pharma | — | |
| “Bullish on smaller CDMO (Contract Development and Manufacturing Organisation) companies, expecting them to deliver stron…” | Vishal ManchandaSystematix Group | Nifty Pharma | — | |
| “Bullish on Pharma and CDMO stocks, observing that they continue to find buyers despite elevated valuations. This indicat…” | VK VijayakumarGeojit Financial Services | Pharma and CDMO | — | |
| “The proposed US tariffs on generic imports, which are not India-specific, are unlikely to significantly impact Indian ph…” | Tushar ManudhaneMotilal Oswal Financial Services | Nifty Pharma | — | |
| “The proposed US tariffs on imported generic medicines create uncertainty for Indian pharmaceutical exporters. While ther…” | Sunny AgrawalSBI Cap Securities | Nifty Pharma | — | |
| “Pharma remains one of the strongest performing sectors, supported by a clear higher-high, higher-low formation and susta…” | Hitesh TailorChoice Equity Broking | Nifty Pharma | — | |
| “Favors the pharmaceuticals sector, seeing significant long-term opportunities in exports, particularly in GLP-1 drugs an…” | Sridhar SivaramEnam Holdings | Pharmaceuticals Sector | — | |
| “Bullish on the Pharma sector, which has broken out of an 18-month consolidation and hit a fresh All-time High. The secto…” | Dharmesh ShahICICI Securities | Nifty Pharma | — | |
| “Pharma is a better dollar play than IT in the current environment, driven by three tailwinds: FII flows, product-specifi…” | Sunil SubramaniamSense and Simplicity | Nifty Pharma | — | |
| “Vora allocates 10-12% of his portfolio to the Pharma sector, indicating a bullish stance. While specific rationale isn't…” | Siddharth VoraPL Asset Management | Nifty Pharma | — | |
| “The Pharma sector is expected to remain range-bound in the short term, having been in a broad consolidation for the past…” | Rupak DeLKP Securities | Nifty Pharma Index | — | |
| “Nimesh Chandan remains constructive on relatively stable sectors like pharma and healthcare. He is positive on these sec…” | Nimesh ChandanBajaj Finserv Asset Management Limited | Nifty Pharma | — | |
| “Carnelian maintains large, untrimmed positions in pharma and CDMOs, viewing CDMOs as a robust long-term manufacturing th…” | Vikas KhemaniCarnelian Asset Management & Advisors | Nifty Pharma | — | |
| “Rohit Srivastava views the pharmaceutical sector as a pure defensive bet during difficult markets. He suggests pharma st…” | Rohit SrivastavaStrike Money Analytics and Indiacharts | Nifty Pharma | — | |
| “Solanki identifies a strategic play in the Pharma sector around upcoming generic drug launches in March (India) and Apri…” | Narendra SolankiAnand Rathi Shares & Stock Brokers | Nifty Pharma | — | |
| “Dipan Mehta advises investors to be overweight on the broader pharma sector. While acknowledging the good opportunity in…” | Dipan MehtaElixir Equities | Nifty Pharma | — | |
| “Nitin Raheja suggests that the pharma sector could see a re-rating in FY27, contingent on supportive valuations. This po…” | Nitin RahejaJulius Baer Wealth Advisors | Nifty Pharma | — | |
| “Continues to stay positive on pharma and healthcare despite a recent pause in performance. This sector remains a preferr…” | Devina MehraFirst Global | Nifty Pharma | — | |
| “Expects sectoral rotation within Pharma, favoring domestic-focused and CDMO (Contract Development and Manufacturing Orga…” | Nilesh ShahKotak AMC | Nifty Pharma | — | |
| “Bullish on the pharmaceuticals sector, citing India's core competence in the area, which positions it to benefit from cu…” | Asit BhandarkarJM Financial MF | Nifty Pharma | — | |
| “Bullish on the Pharmaceuticals sector, identifying it as a promising multi-year story. Strong opportunities in CDMO, con…” | Jitendra SriramBaroda BNP Paribas Mutual Fund | Nifty Pharma | — | |
| “Bullish on Pharma (CDMOs) companies, projecting earnings growth of 25-30% and expecting them to outperform in the next m…” | Aditya SoodInCred Asset Management | Nifty Pharma | — | |
| “Bullish on the Pharma sector, which has shown consistent sales growth over the last four years. The Nifty Pharma index r…” | Apurva ShethSamco Securities | Nifty Pharma | — | |
| “Bullish on the Pharma sector, citing multi-year earnings visibility, improving growth trajectories, and reasonable PEG r…” | Abhay AgarwalPiper Serica | Nifty Pharma | — | |
| “Bearish on the Generic Pharma sector for FY27, despite strong near-term momentum. Earnings decline is likely after two o…” | Amey ChalkeJM Financial | Nifty Pharma | — | |
| “Bullish on select pharma stocks including Lupin, Zydus, and Torrent Pharma, noting they are showing good traction. The s…” | Dharmesh KantCholamandalam Securities | Nifty Pharma | — | |
| “Bullish on the Pharma sector, anticipating its revival to contribute to a stronger market rebound in FY27. This sector, …” | Jaiprakash ToshniwalLIC MF Asset Management | Nifty Pharma | — | |
| “Bullish on the pharma sector, highlighting Divi’s Laboratories and Torrent Pharma as key players benefiting from sustain…” | Chakri LokapriyaLGT Wealth | Nifty Pharma | — | |
| “Bullish on the pharma sector, focusing on companies with strong pipelines and reasonable valuations. The fund is finding…” | Christy MathaiQuantum AMC | Nifty Pharma | — | |
| “Bullish on the pharma sector, seeing strong promise in the Contract Development and Manufacturing Organization (CDMO) se…” | Anshul SaigalSaigal Capital | Nifty Pharma | — | |
| “Bullish on the pharma sector for the next year, seeing it as a key opportunity to lead the next rally. This comes as par…” | Sailesh Raj BhanNippon India Mutual Fund | Nifty Pharma | — | |
| “Increasingly bullish on pharma companies that invest in IP, ANDAs, and novel drug development, particularly those filing…” | Ramesh DamaniBombay Stock Exchange | Nifty Pharma | — | |
| “Nomura is bullish on the Pharmaceuticals sector, shifting from a tactically cautious stance. The firm maintains a strate…” | Nomura AnalysisNomura Global Markets Research | Nifty Pharma | — | |
| “Lupin remains a top pick within the pharma sector due to its strong product pipeline, consistent performance in the US m…” | Rahul ShahMotilal Oswal Financial Services | Nifty Pharma | — | |
| “Bullish on domestic-focused pharma companies, which are growing at a 25% CAGR. Recommends companies with limited US expo…” | Sudip BandyopadhyayIndependent | Nifty Pharma | — | |
| “Maintains a bullish stance on the pharma sector, believing global tariff concerns will not significantly impact Indian c…” | Daljeet KohliRoha Asset Managers LLP | Nifty Pharma | — | |
| “Bullish on the pharma sector, seeing opportunities post-correction due to limited impact from US tariff concerns. This s…” | Sachin ShahEmkay Investment Managers | Nifty Pharma | — | |
| “Bullish on the Indian Pharma sector, noting that while recent tariff news has spooked markets, the impact on Indian gene…” | Devang MehtaSpark Capital Private Wealth | Nifty Pharma | — | |
| “Bullish on Indian generic pharma companies, expecting no impact from Trump's conditional tariffs on branded/patented dru…” | Tushar ManudhaneMotilal Oswal Financial Services | Nifty Pharma | — | |
| “Bullish on Indian pharma stocks like Zydus Life, Aurobindo Pharma, Dr Reddy's Lab, Lupin, Sun Pharma, Cipla, and Gland P…” | Avinash GorakshkarIndependent | Nifty Pharma | — | |
| “Neutral on the Indian pharma sector, as the impact of recent 100% tariffs on patented and branded drugs is expected to b…” | Shreyash DevalkarAxis Mutual Fund | Nifty Pharma | — | |
| “Bullish on specific generic pharma stocks like Sun Pharma, Lupin Labs, and Cipla, considering them attractive. Dr Reddy'…” | Amnish AggarwalPrabhudas Lilladher Capital | Nifty Pharma | — | |
| “JPMorgan remains constructive on the Indian pharmaceutical sector, particularly the generic drugs segment, despite tarif…” | Bansi DesaiJPMorgan | Nifty Pharma | — | |
| “Bearish on the pharma sector due to concerns over patent expiries, which are expected to impact earnings.” | Nikhil RankaNuvama Asset Management | Nifty Pharma | — | |
| “Reiterates a long-held bullish stance on the pharma sector, dismissing fears around potential US tariffs. He believes In…” | Sandeep TandonQuant Mutual Fund | Nifty Pharma | — | |
| “Bullish on the Pharma sector, identifying it as a strong segment with potential to perform well. This aligns with his vi…” | Vikas KhemaniIndependent | Nifty Pharma | — | |
| “Recommends profit-taking in the pharma sector due to concerns over US generics, including potential Section 232 investig…” | Rajiv BatraJPMorgan | Nifty Pharma | — | |
| “Bullish on the pharma sector from a medium to long-term perspective, viewing current uncertainties due to potential US t…” | Sunny AgrawalSBI Cap Securities | Nifty Pharma | — | |
| “Bearish on the Pharma sector in the near term, expecting time correction due to high valuations, especially for CDMO pla…” | Sneha PoddarMotilal Oswal Financial Services | Nifty Pharma | — | |
| “Bullish on the Pharma sector, viewing the recent 1-2 month correction as a great buying opportunity. This is due to no t…” | Rajat SharmaSana Securities | Nifty Pharma | — | |
| “Bullish on the Pharma sector, expecting it to outperform in the near term. This aligns with the broader market's potenti…” | Sameet ChavanAngel One | Nifty Pharma | — | |
| “Bullish on the Pharmaceuticals sector, recommending accumulation of quality large-caps. The current market correction pr…” | Somil MehtaMirae Asset ShareKhan | Nifty Pharma | — | |
| “Bullish on quality pharma stocks, viewing tariff-induced volatility as an opportunity for investors to accumulate on dip…” | Ajit BanerjeeShriram Life Insurance | Nifty Pharma | — | |
| “Bearish on Indian pharmaceutical companies that rely heavily on exports to the US. Trump's announced tariff hikes, event…” | Arvind SangerGeosphere Capital | Nifty Pharma | — | |
| “Bullish on Indian pharmaceutical companies, expecting them to thrive due to relaxed US regulations and the ability to op…” | Pashupati AdvaniGlobal Foray | Nifty Pharma | — | |
| “Bullish on the pharma sector structurally, despite potential short-term adjustments for a quarter or two due to tariff a…” | Vikas KhemaniCarnelian Asset Management & Advisors | Nifty Pharma | — | |
| “Bullish on the pharmaceuticals sector, specifically contract research, manufacturing, and API segments, for long-term po…” | Deven ChokseyDRChoksey FinServ Pvt. Ltd | Nifty Pharma | — | |
| “Bullish on the pharma segment, which is performing better within the defensive pack due to reasonably good domestic and …” | Amnish AggarwalPrabhudas Lilladher Capital | Nifty Pharma | — | |
| “Bullish on the Pharma sector as a defensive play. While past underperformance was due to FII selling and 'Trump effect' …” | Sunil SubramaniamIndependent | Nifty Pharma | — | |
| “The Pharma Index is exhibiting strength by forming a higher top–higher bottom structure, indicating a positive short-ter…” | Nilesh JainCentrum Finverse Ltd. | Nifty Pharma | — | |
| “Bullish on the Pharma sector, which has shown outperformance in the last two weeks and is expected to continue its upwar…” | Arpan ShahMonarch Networth Capital | Nifty Pharma | — | |
| “Pharma is facing significant challenges, particularly the threat of a 200% tariff on exports to the US, which accounts f…” | Abhishek BanerjeeLotusDew Wealth | Nifty Pharma | — | |
| “Bullish on the Indian pharma sector, especially largecap and some midcap companies, following the delay in US tariff ann…” | Sudip BandyopadhyayInditrade Capital | Nifty Pharma | — | |
| “Bullish on the healthcare/pharma sector, expecting 11% growth this quarter. The sector has consistently delivered low to…” | Siddhartha KhemkaMotilal Oswal Financial Services Ltd. | Nifty Pharma | — | |
| “Bullish on the Pharma sector, identifying Glenmark, Laurus Labs, and Biocon as promising stocks. He recommends buying th…” | CA Rudramurthy BVVachana Investments | Nifty Pharma | — | |
| “Bullish on Indian pharma, believing tariff-related uncertainty is overdone as the US cannot afford huge tariffs without …” | Sudip BandyopadhyayInditrade Capital | Nifty Pharma | — | |
| “Bullish on several Indian sectors positioned to attract global capital and scale under the China+1 strategy. These inclu…” | Kedar KadamDolat Capital | Nifty Pharma | — | |
| “Bullish on the pharma sector, noting significant recovery in earnings over the last two years due to solid investments b…” | Abhay AgarwalPiper Serica | Nifty Pharma | — | |
| “Considers Pharma one of the best 'go-to' sectors, highlighting Divi’s Labs, Laurus Labs, and Biocon as very attractive s…” | CA Rudramurthy BVVachana Investments | Nifty Pharma | — | |
| “Bullish on the pharmaceuticals sector, identifying selective opportunities for the second half of 2025. Several names in…” | Arun PatelArunasset Investment Services | Nifty Pharma | — | |
| “Bullish on the Pharma index, which is breaking out of a multi-month consolidation around the 22,200 area. Expects the in…” | Rahul SharmaJM Financial Services | Nifty Pharma | — | |
| “Bullish on the Pharma, Healthcare, and Hospitals sectors, expecting them to continue delivering reasonable numbers in th…” | Amnish AggarwalPrabhudas Lilladher Capital | Nifty Pharma | — | |
| “The pharmaceutical sector offers strong opportunities due to solid domestic fundamentals and positive global trends like…” | Viraj GandhiSAMCO Mutual Fund | Nifty Pharma | — | |
| “Advises a neutral stance on the pharma sector for FY26, anticipating a consolidation year. This is due to normalizing ta…” | Amit KhuranaDolat Capital | Nifty Pharma | — | |
| “Bullish on defensive sectors like Pharma and FMCG for the next one to two weeks, expecting them to hold out better or pr…” | Rohit SrivastavaStrike Money Analytics and Indiacharts | Nifty Pharma | — | |
| “Very bullish on the pharma sector, identifying Divi's Lab, Laurus Lab, Glenmark, and Biocon as attractive buying opportu…” | CA Rudramurthy BVVachana Investments | Nifty Pharma | — | |
| “Distinctly confident about the prospects of the pharma sector going forward, despite tariff turbulence. Indian companies…” | Deven ChokseyDRChoksey FinServ Pvt. Ltd | Nifty Pharma | — | |
| “Bullish on the Pharma sector as a contrarian play, expecting stronger players to benefit. Despite concerns about US regu…” | Mittul KalawadiaICICI Prudential AMC | Nifty Pharma | — | |
| “Maintains a bullish view on the pharmaceuticals industry, which appears well-positioned for FY26 and beyond. This is sup…” | Axis Securities AnalysisAxis Securities | Nifty Pharma | — | |
| “Bullish on select pharma counters, having added to these names. This aligns with a broader strategy of individual stock …” | Shreyash DevalkarAxis Mutual Fund | Pharma | — | |
| “Bearish on the Pharma sector, expecting a very challenging FY26. The sector's recent result season was subdued, and ther…” | Nikhil RankaNuvama Asset Management | Nifty Pharma | — | |
| “Constructive on Indian pharma and CDMO companies, seeing 7-49% upside potential. The recent correction in pharma offers …” | Macquarie AnalysisMacquarie Capital Securities | Nifty Pharma | — | |
| “Overweight on financials, consumption, and pharma sectors. Recommends accumulating good quality companies at reasonable …” | Harshad BorawakeMirae Asset Investment Managers (India) | Nifty Pharma | — | |
| “Bearish on the pharma sector in the near term due to uncertainty surrounding potential US tariffs. While tariffs haven't…” | Hemant KanawalaKotak Life Insurance | Nifty Pharma | — | |
| “Bullish on the Pharma sector, identifying it as a potential driver for the next leg of market momentum. He considers cur…” | Deven ChokseyDRChoksey FinServ Pvt. Ltd | Nifty Pharma | — | |
| “Bullish on the pharmaceuticals sector, anticipating increased demand from US pharmaceutical companies seeking lower-pric…” | Mark MobiusMobius Emerging Opportunities Fund | Nifty Pharma | — | |
| “Bearish on the pharma sector due to renewed concerns over US policy, including President Trump’s executive order to boos…” | Amar K AmbaniYes Securities | Nifty Pharma | — | |
| “Bullish on the pharma sector despite news around tariffs, believing any tariffs will not be disruptive and largely borne…” | Aniruddha NahaPGIM India Asset Management | Nifty Pharma | — | |
| “Very positive on the pharma sector, specifically focusing on CRAMS (Contract Research and Manufacturing Services) and do…” | Sorbh GuptaBajaj Finserv Asset Management | Nifty Pharma | — | |
| “Bullish on the Pharma sector, noting it looks good at this point in time. Also likes the PSU banking space, believing it…” | Sneha SethAngel One | Nifty Pharma | — | |
| “Bullish on the Pharma sector, particularly Contract Development and Manufacturing Organizations (CDMOs), viewing it as a…” | Anshul SaigalSaigal Capital | Nifty Pharma | — | |
| “Bullish on the Indian pharma sector, which contributes over $400 billion in annual savings to the US healthcare system, …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Nifty Pharma | — | |
| “Positive on Sun Pharma, Dr Reddy’s, and Lupin despite tariff announcements, viewing the recent dip as a buying opportuni…” | Gaurang ShahGeojit Investments | Nifty Pharma | — | |
| “Nifty Pharma's immediate support is at 19,650, which aligns with the 20-month moving average on monthly charts, making i…” | Anshul JainLakshmishree | Nifty Pharma | — | |
| “Nifty Pharma is experiencing high volatility and a major sell-off, with prices down over 5%. The next support levels are…” | Rajesh BhosaleAngel One | Nifty Pharma | — | |
| “Positive on the pharma sector, especially US generics like Sun Pharma, following the non-implementation of reciprocal ta…” | Siddhartha KhemkaMotilal Oswal Financial Services Ltd. | Nifty Pharma | — |
Composition
20 stocks
Member stocks, ranked by today's change — biggest gainers first, biggest losers last.
ABBOTINDIA
Abbott India Ltd. · Healthcare
₹26,525
+3.23%
TORNTPHARM
Torrent Pharmaceuticals Ltd. · Healthcare
₹4,689.5
+1.70%
GLENMARK
Glenmark Pharmaceuticals Ltd. · Healthcare
₹2,648
+1.51%
AJANTPHARM
Ajanta Pharmaceuticals Ltd. · Healthcare
₹3,317.7
+1.45%
MANKIND
Mankind Pharma Ltd. · Healthcare
₹2,665
+1.37%
GLAND
Gland Pharma Ltd. · Healthcare
₹3,331.9
+1.18%
ALKEM
Alkem Laboratories Ltd. · Healthcare
₹5,185
+0.78%
LUPIN
Lupin Ltd. · Healthcare
₹2,014
+0.76%
SAILIFE
Sai Life Sciences Ltd. · Healthcare
₹1,800.7
+0.69%
BIOCON
Biocon Ltd. · Healthcare
₹364.4
+0.21%
DIVISLAB
Divi's Laboratories Ltd. · Healthcare
₹11,180.5
+0.02%
WOCKPHARMA
Wockhardt Ltd. · Healthcare
₹2,184.4
-0.12%
PPLPHARMA
Piramal Pharma Ltd. · Healthcare
₹239.3
-0.15%
ZYDUSLIFE
Zydus Lifesciences Ltd. · Healthcare
₹1,200
-0.24%
CIPLA
Cipla Ltd. · Healthcare
₹1,415
-0.25%
AUROPHARMA
Aurobindo Pharma Ltd. · Healthcare
₹1,799
-0.37%
LAURUSLABS
Laurus Labs Ltd. · Healthcare
₹2,294.6
-0.49%
DRREDDY
Dr. Reddy's Laboratories Ltd. · Healthcare
₹1,390.2
-0.76%
SUNPHARMA
Sun Pharmaceutical Industries Ltd. · Healthcare
₹1,884.9
-0.79%
IPCALAB
Ipca Laboratories Ltd. · Healthcare
₹1,843.8
-0.87%
ETFs tracking this index
2 funds
Index levels are informational only, not investment advice.
Piramal Pharma Share Price Today Down 2.44%: What It Shows
Piramal Pharma shares fell to Rs 189.70, down 2.44% from the prior close of Rs 194.45, after opening near Rs 194.70 and reaching an intraday high of Rs 199.50. The decline occurs amid a large‑cap company reporting a P/B of 3.23x, negative ROE of 4.04% and EPS of Rs ‑2.36, figures that lag industry benchmarks.
How JSW Steel, Dr Reddy’s, Mankind Pharma are fine-tuning AI investments
Mankind Pharma’s global CFO, Ashutosh Dhawan, highlighted the company’s AI strategy at the ETCFO Annual Conclave, stressing the need to balance immediate productivity gains with long‑term capability building. Dhawan noted that Mankind Pharma is prioritising AI projects that deliver measurable operational efficiencies while also investing in foundational data and compliance systems that may not show instant ROI. This dual approach aims to strengthen future competitiveness without compromising current financial discipline.
Cipla - IndiGo, Tata Motors PV among 10 Nifty stocks facing earnings downgrades
The Economic Times · 3 days ago
Gland Pharma Holders Are Up 93% And Here Is What They Saw
Gland Pharma’s shares have risen about 93% year‑to‑date, reaching roughly ₹3,293 from ₹1,715 at the start of 2026. The rally follows a U.S. FDA approval for a methylprednisolone injectable, which helped lift quarterly revenue to ₹18.34 billion and improve net margin to 15.9%, prompting optimistic fair‑value estimates despite some analysts warning of capacity‑utilisation risks.
Alkem Labs shares fall 2% as US FDA issues warning letter to its Daman manufacturing facility
Upstox · 3 days ago
Piramal Pharma acquisition: Company to buy remaining 26% stake in Yapan Bio
BusinessLine · 4 days ago
Stocks for quick gains: Know target price, stop loss for GAIL, Tata Consumer and Cipla
Cipla shares have rebounded above key moving‑average support, with the RSI at 62.07 indicating growing buying pressure. Choice Broking’s analyst recommends buying at ₹1,417, setting a stop‑loss at ₹1,345 and targeting ₹1,560, which could yield roughly a 10.1% return if the bullish trend continues.
Sai Life Sciences rises 2.11% in Wednesday's session
Global Banking & Finance Review · 4 days ago
Glenmark Pharma shares rise over 2% as unit files US application for experimental solid-tumour drug
Moneycontrol.com · 5 days ago
LINK PHARMA Share Price Today Up 11%
Gland Pharma shares rose about 80% over the past twelve months, making it one of the top gainers in the BSE Healthcare index. The surge contrasts with broader market trends, as the BSE Healthcare index gained 17.8% while the BSE Sensex fell 3.2% in the same period.
Oyster Renewable Invests INR 372 Crore In 60.9 MW Wind-Solar Hybrid Project For Laurus Labs In Andhra Pradesh
SolarQuarter · 5 days ago
Glenmark shares gain 2% to ₹2,673 after IND filing for first in class pentaspecific cancer antibody ISB 2301
Business Upturn · 5 days ago
Lupin: Nomura raises target price to Rs 2,780, sees nearly 40% upside as valuations turn attractive
Moneycontrol.com · 5 days ago
Pharma sector stocks today, November 17: Aarti Drugs jumps 1.60%, Wockhardt up 1.43%, Zydus Life rises 0.98%
Business Upturn · 6 days ago